Global Alpha Thalassemia Treatment Market Research Report 2023-Competitive Analysis, Status and Outlook by Type, Downstream Industry, and Geography, Forecast to 2029

Global Alpha Thalassemia Treatment Market Research Report 2023-Competitive Analysis, Status and Outlook by Type, Downstream Industry, and Geography, Forecast to 2029

Alpha thalassemia causes due to deficiency or absence of alpha globin chains results in alpha thalassemia which is asymptomatic with general hematologic findings and gains silent carrier status.

Market Overview:

The latest research study on the global Alpha Thalassemia Treatment market finds that the global Alpha Thalassemia Treatment market reached a value of USD 563.41 million in 2022. It’s expected that the market will achieve USD 306.2 million by 2028, exhibiting a CAGR of -9.66% during the forecast period.

Region Overview:

In 2022, the share of the Alpha Thalassemia Treatment market in Asia-Pacific stood at 82.83%.

Company Overview:

Novartis AG is one of the major players operating in the Alpha Thalassemia Treatment market, holding a share of 44.77% in 2020.

Novartis AG

Novartis AG manufactures pharmaceutical and consumer healthcare products. The Company uses innovative science and digital technologies to create transformative treatments in areas of great medical need. Novartis offers patent protected prescription medicine and generic pharmaceuticals and biosimilars.

ApoPharma Inc.

ApoPharma Inc's research focus is on the use of medicines to treat disorders caused or worsened by excessive iron or faulty processing of iron in cells in the body. These disorders include both generalized iron overload, which affects patients who must undergo repeated blood transfusions, and localized iron dysregulation in the brain, which underlies a number of neurological disorders such as pantothenate kinase-associated neurodegeneration and Parkinson's disease.

Segmentation Overview:

As for product types, the Deferasirox segment held the largest market share in 2022.

Application Overview:

The market's largest segment by application is the segment Hospitals, with a market share of 89.99% in 2022.

Key Companies in the global Alpha Thalassemia Treatment market covered in Chapter 3:

Teva
Bristol Myers Squibb
Bio-Tech Pharmacal
BY-Health Co Ltd
Novartis AG
ApoPharma Inc.
LIPOMED
Medicamen Biotech Ltd

In Chapter 4 and Chapter 14.2, on the basis of types, the Alpha Thalassemia Treatment market from 2018 to 2029 is primarily split into:

Folic Acid
Deferasirox
Deferiprone
Hydroxyurea

In Chapter 5 and Chapter 14.3, on the basis of Downstream Industry, the Alpha Thalassemia Treatment market from 2018 to 2029 covers:

Hospitals
Ambulatory Surgical Center

Geographically, the detailed analysis of consumption, revenue, market share and growth rate, historic and forecast (2018-2029) of the following regions are covered in Chapter 8 to Chapter 14:

North America (United States, Canada)
Europe (Germany, UK, France, Italy, Spain, Russia, Netherlands, Turkey, Switzerland, Sweden)
Asia Pacific (China, Japan, South Korea, Australia, India, Indonesia, Philippines, Malaysia)
Latin America (Brazil, Mexico, Argentina)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa)